Novel PET agent could outperform FDG for tumor diagnosis, early data suggest

07/30/2013 | MolecularImaging.net

A study published in the Journal of Nuclear Medicine suggests a new fluorine-based PET agent may perform comparably and possibly better than FDG for oncology imaging. The agent 2-Deoxy-2-18F-fluoro-D-mannose, known as FDM, was assessed through in vitro and in vivo evaluations in small animals with AH109A tumor cells to examine uptake and metabolism of the agent. "F-18 FDM showed high accumulation in tumors, lower uptake in the brain than that of F-18 FDG, and rapid excretion from the blood, indicating promising characteristics for cancer imaging," researchers wrote.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC